Asset Details
Do you wish to reserve the book?
Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes
Do you wish to request the book?
Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes
2025
Overview
Background Post‐embolization syndrome after transarterial chemoembolization (TACE) and Yttrium‐90 radioembolization (TARE) causes significant morbidity. Understanding whether discharge prescriptions influence short‐term outcomes may guide standardized pain‐management strategies. Methods A retrospective cohort study of 3191 patients (3988 procedures) with hepatocellular carcinoma from the Merative MarketScan Databases (2009–2022) was performed. The composite outcome was 7‐day drug escalation or hospital readmission. Bivariate logistic regression identified candidate variables (p < 0.10); multivariable logistic regression with patient‐clustered robust standard errors estimated adjusted odds ratios (aORs), adjusting for age, sex, and Charlson Comorbidity Index (CCI). Results Compared to patients discharged without opioids post‐chemoembolization, those prescribed opioids at discharge had 83% lower odds of experiencing drug escalation or readmission (odds ratio [aOR] = 0.17, p < 0.001), and those undergoing radioembolization had 59% lower odds (aOR = 0.41, p < 0.001). Being prescribed antiemetics or steroids was also associated with lower odds of escalation/readmission events, with percentages varying by procedure type. Conclusions Prescribing opioids, along with antiemetics and steroids, at discharge may reduce the likelihood of post‐procedural events, such as drug escalation and readmission, in patients undergoing trans‐arterial chemoembolization and radioembolization for hepatocellular carcinoma. These findings highlight the importance of a comprehensive pain management strategy in interventional oncology and warrant consideration in clinical practice guidelines.
Publisher
John Wiley & Sons, Inc,Wiley
Subject
/ Analgesics, Opioid - therapeutic use
/ Antiemetics - therapeutic use
/ Carcinoma, Hepatocellular - therapy
/ Chemoembolization, Therapeutic - adverse effects
/ Female
/ Humans
/ Male
/ Medicare
/ Opioids
/ Pain
/ Patient Discharge - statistics & numerical data
/ Patient Readmission - statistics & numerical data
/ Patients
/ Yttrium
